The Diagnostic Power of the Platelet Mass Index for Testicular Tumours: A Simple Blood Test
El poder diagnóstico del índice de masa plaquetaria para los tumores testiculares: un simple análisis de sangre
Reha Girgin, Önder Çınar, Ersan Bulut, Bülent Akduman, Gökhan Çeker
Abstract
Introduction: The relationship between inflammation and cancer has long been the focus of researchers' interest. There are many inflammatory markers studied for this purpose in the literature. In this context, we focused on the effects of platelet counts and platelet mass index (PMI) as inflammatory markers in the diagnosis of low-volume localized testicular cancer.
Materials and methods: Thirty-eight patients with localized testicular cancer with a mean age of 30.84 ± 5.79 years and 38 patients with varicocele as a control group with a mean age of 32.8 ± 9.7 years were enrolled in the study. Number of platelets, mean platelet volume and value of PMI were calculated from peripheral blood samples obtained.
Results: Number of platelets and PMI values were statistically significantly higher in patients with testicular cancer compared with the control group (p<.05).
Conclusions: Both platelet counts and PMI values can be used as a simple test in the diagnosis of testicular cancer besides the well-known accurate serum tumor markers as AFP (alpha fetoprotein), hCG (human chorionic gonadotropin) and LDH (lactate dehydrogenase).
Keywords
Resumen
Introducción: La relación entre la inflamación y el cáncer ha sido durante mucho tiempo el foco de interés de los investigadores. Hay muchos marcadores inflamatorios estudiados con este propósito en la literatura. En este contexto, nos centramos en los efectos del recuento de plaquetas y el índice de masa plaquetaria (PMI) como marcadores inflamatorios en el diagnóstico de cáncer testicular localizado de bajo volumen.
Materiales y métodos: Se incluyeron en el estudio 38 pacientes con cáncer testicular localizado con una edad media de 30,84 ± 5,79 años y 38 pacientes con varicocele como grupo control con una edad media de 32,8 ± 9,7 años. El número de plaquetas, el volumen medio de plaquetas y el valor de PMI se calcularon a partir de muestras de sangre periférica obtenidas.
Resultados: El número de plaquetas y los valores de PMI fueron estadísticamente significativamente más altos en los pacientes con cáncer testicular en comparación con el grupo de control (p <.05).
Conclusiones: Tanto el recuento de plaquetas como los valores de PMI se pueden utilizar como una prueba simple en el diagnóstico de cáncer testicular, además de los marcadores tumorales séricos precisos bien conocidos como AFP (alfa fetoproteína), hCG (gonadotropina coriónica humana) y LDH (lactato deshidrogenasa).
Palabras clave
References
1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0.
2. Gong L, Cumpian AM, Caetano MS, Ochoa CE, De la Garza MM, Lapid DJ, et al. Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer. 2013;12(1):154. doi: 10.1186/1476-4598-12-154.
3. Asari S, Matsumoto I, Toyama H, Shinzeki M, Goto T, Ishida J, et al. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today. 2016;46(5):583-92. doi: 10.1007/s00595-015-1206-3.
4. Moris D, Damaskos C, Spartalis E, Papalampros A, Vernadakis S, Dimitroulis D, et al. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Anticancer Res. 2017;37(5):2185-94. doi: 10.21873/anticanres.11553.
5. Linke B, Schreiber Y, Picard-Willems B, Slattery P, Nüsing RM, Harder S, et al. Activated Platelets Induce an Anti-Inflammatory Response of Monocytes/Macrophages through Cross-Regulation of PGE2 and Cytokines. Mediators Inflamm. 2017;2017:1463216. doi: 10.1155/2017/1463216.
6. Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelets effects on tumor growth. Semin Oncol. 2014;41(3):359-69. doi: 10.1053/j.seminoncol.2014.04.006.
7. Goubran H, Sabry W, Kotb R, Seghatchian J, Burnouf T. Platelet microparticles and cancer: An intimate cross-talk. Transfus Apher Sci. 2015;53(2):168-72. doi: 10.1016/j.transci.2015.10.014.
8. Demir N, Peker E, Ece İ, Ağengin K, Bulan KA, Tuncer O. Is platelet mass a more significant indicator than platelet count of closure of patent ductus arteriosus? J Matern Fetal Neonatal Med. 2016;29(12):1915-8. doi: 10.3109/14767058.2015.1067296.
9. Arda E, Cakiroglu B, Cetin G, Yuksel I. Metachronous Testicular Cancer After Orchiectomy: A Rare Case. Cureus. 2017;9(11):e1833. doi: 10.7759/cureus.1833.
10. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24(4):878-88. doi: 10.1093/annonc/mds579.
11. Yuksel OH, Verit A, Sahin A, Urkmez A, Uruc F. White blood cell counts and neutrophil to lymphocyte ratio in the diagnosis of testicular cancer: a simple secondary serum tumor marker. Int Braz J Urol. 2016;42(1):53-9. doi: 10.1590/S1677-5538.IBJU.2014.0593.
12. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol. 2013;35(3):254-61. doi: 10.1111/ijlh.12084.
13. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126(5):582-8. doi: 10.1182/blood-2014-08-531582.
14. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504-8. doi: 10.1038/clpt.2009.254.
15. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283-7. doi: 10.1023/B:AGEN.0000029415.62384.ba.
16. Can C, Baseskioglu B, Yılmaz M, Colak E, Ozen A, Yenilmez A. Pretreatment parameters obtained from peripheral blood sample predicts invasiveness of bladder carcinoma. Urol Int. 2012;89(4):468-72. doi: 10.1159/000343278.
17. Lee H, Jeong SJ, Hong SK, Byun SS, Lee SE, Oh JJ. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. World J Urol. 2016;34(6):821-7. doi: 10.1007/s00345-015-1701-6.
18. Ipekci T, Yuksel M, Ucar M, Tunckıran A, Kozacıoglu Z, Akman RY. Is Preoperative Neutrophil Lymphocyte Ratio a Reliable Prognostic Parameter for Localized Prostate Cancer? Bull Urooncol. 2017;16:119-22.
19. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010;184(3):873-8. doi: 10.1016/j.juro.2010.05.028.
20. Kobayashi M, Kubo T, Komatsu K, Fujisaki A, Terauchi F, Natsui S, et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol. 2013;30(2):556. doi: 10.1007/s12032-013-0556-1.
21. Hashimoto T, Ohno Y, Nakashima J, Gondo T, Ohori M, Tachibana M. Clinical significance of preoperative peripheral blood neutrophil count in patients with non-metastatic upper urinary tract carcinoma. World J Urol. 2013;31(4):953-8. doi: 10.1007/s00345-012-0942-x.
22. Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 2012;72(18):4662-71. doi: 10.1158/0008-5472.CAN-11-4010.
23. Wang J, Liu Y, Zhang N, Li X, Xin P, Bi J, et al. Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer. Oncotarget. 2017;8(41):70874-82. doi: 10.18632/oncotarget.20147.
24. Ekici H, Malatyalioglu E, Kokcu A, Kurtoglu E, Tosun M, Celik H. Do Leukocyte and Platelet Counts Have Benefit for \Preoperative Evaluation of
Endometrial Cancer? Asian Pac J Cancer Prev. 2015;16(13):5305-10. doi: 10.7314/apjcp.2015.16.13.5305.
25. Pietrzyk L, Plewa Z, Denisow-Pietrzyk M, Zebrowski R, Torres K. Diagnostic Power of Blood Parameters as Screening Markers in Gastric Cancer Patients. Asian Pac J Cancer Prev. 2016;17(9):4433-7.
26. Shen XM, Xia YY, Lian L, Zhou C, Li XL, Han SG, et al. Mean platelet volume provides beneficial diagnostic and prognostic information for patients with resectable gastric cancer. Oncol Lett. 2016;12(4):2501-6. doi: 10.3892/ol.2016.4913.
27. Wang X, Cui MM, Xu Y, Liu L, Niu Y, Liu T, et al. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget. 2017;8(40):68115-22. doi: 10.18632/oncotarget.19242.
28. Zhang F, Chen Z, Wang P, Hu X, Gao Y, He J. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumour Biol. 2016;37(7):9323-31. doi: 10.1007/s13277-015-4774-3.
29. Gu M, Zhai Z, Huang L, Zheng W, Zhou Y, Zhu R, Shen F, Yuan C. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2016;23(5):752-60. doi: 10.1007/s12282-015-0635-6.
30. Girgin R, Çınar Ö, Bulut E, Önal CF. Does Platelet Mass Index Play a Role in Predicting Biochemical Recurrence in Localized Prostate Cancer? J Urol Surg 2018;5:164-9. doi: 10.4274/jus.1960.
Submitted date:
05/22/2021
Reviewed date:
06/22/2021
Accepted date:
07/01/2021
Publication date:
07/01/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email